If I had to look at this objectively and un-biased, the
If I had to look at this objectively and un-biased, the other investors in this group must have considered the baggage from Tony and Pestell. They can't be super stupid to think all the non-5% investors would look past these 2 individuals. I am all for some talented board members and a replacement for Nader IF they actually have something to offer. We don't know yet but the 5% are already starting off in the ditch with Tony and Pestell.
The big criticism of Nader is a lack of industry experience and a rough on the edges communication style. If a candidate was proposed with a real plan to get to the next level, great. I don't see much of anything to suggest Rosenbaum is any better suited than Nader. Patterson may be an asset, however he likely would not have any interest unless the whole board and management team was replaced.
My guess is that this 5% have a plan that has been in the making for some time. The 13d filing was a "no turning back" moment for this group. They made the call that enough was enough in there minds. I do think the compensation committee vote to enrich the BOD and mgmt. team was part of a defense against this group years ago, the lawsuit was a response to it knowing that unless they removed the shares given to the BOD and mgmt., they would not be able to get to 5% as easily. This 13d being filed so soon after the lawsuit settlement is not a coincidence.
What is the 5% plan? I remember Nader mentioning a low-ball offer years ago that he had to fight against. It could be Tony was working on a deal which would explain the silence at that time. I feel the plan is that they want to take control and sell the company ASAP. I don't think they have any idea how to run the company or what they would do differently etc..
don't get me wrong, If Nader really has hit a wall and just can't get this across the finish line for whatever reason, then partnering/selling might be the best option. It could be the gap between what Nader thinks cytodyn is worth and what is being offered is maybe that Nader has a crazy high number in his head that really scared away all opportunities. Could be the opportunities found this 5% group to be there best option to get ownership of the drug. This could really blow up in the 5% face also. The BP that might be watching this could really be using this to smother cytodyn.
As much as the next few months will be a rollercoaster of trial results and possible purchase orders, there will also be a big effort to derail and distract. As if getting a drug approved was not enough.
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...
Continue Reading
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....
Continue Reading
Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...
Continue Reading
When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...
Continue Reading
Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...
Continue Reading
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...
Continue Reading
Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...
Continue Reading
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue Reading
Top 5 Most Recently Viewed Articles
Viatris Launches Cash Tender Offers for Outstanding Notes Viatris Inc. (NASDAQ: VTRS), a leading player in the global healthcare sector, has initiated tender offers to acquire certain outstanding notes. This move is designed to strengthen its financial framework and enhance returns for its shareholders. Notably, the offers include various senior notes that were originally...
Continue Reading
Coke Florida Kicks Off Holiday Spirit with Caravan Tour Coca-Cola Beverages Florida, LLC (Coke Florida) is thrilled to share that its beloved annual "Holiday Caravan" is set to return. This event, which has become an essential part of the holiday season, features the iconic Coca-Cola red delivery truck decked out in festive cheer. Families will enjoy complimentary samples...
Continue Reading
Nexxen's Upcoming Participation at RBC Global Conference Nexxen International Ltd. (AIM/NASDAQ: NEXN), a leading global advertising technology platform, is geared up to take part in a significant event, the RBC Global Technology, Internet, Media and Telecommunications Conference. This event provides a stellar opportunity for companies to connect with investors and share...
Continue Reading
GayVeterans.us Achieves 501(c)(3) Tax Exempt Status GayVeteransUS-Inc. has recently been granted 501(c)(3) tax-exempt status, marking a significant milestone for the organization. This designation enables supporters to make tax-deductible contributions, strengthening the community's ability to provide enhanced resources and support. The dedication of veteran volunteers...
Continue Reading
Virbac Enhances Its Offerings with Felanorm Acquisition Virbac has announced a significant acquisition that marks a pivotal moment in its commitment to improving the health and quality of life for senior cats. This globally recognized drug is aimed at treating feline hyperthyroidism, a condition that is becoming increasingly common in older cats. Understanding Feline...
Continue Reading